Clinical Efficacy of Levonorgestrel Releasing Intrauterine System for the Treatment of Adenomyosis in Perimenopausal Women

Background: The aim of this study was to evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena) in the treatment of menorrhagia, dysmenorrhea and poor quality of life caused by adenomyosis in perimenopausal women. Patients and methods: Ninety-six women with menorrhagia, dysmenorrhea and poor quality of life with adenomyosis in perimenopausal women were included and were invited to complete a SF-36 Health Survey. Exclude cervical and endometrial lesions through underwent a Pap smear, transvaginal sonography and endometrial biopsy. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC), and dysmenorrhea intensity was assessed by a visual analogue scale (VAS). They were followed up after 1 month, 3 months, 6 months, 12 months, and after 18 months. The participations are asked to complete the short form 36 (SF-36) health survey questionnaires. Results: The menstrual blood size was (60.287 ± 21.832) (41.186 ± 16.153), (30.988 ± 15.670), (19.238 ± 13.649), (16 ± 11.464) after treatment 1, 3, 6, 12, and after 18 months, respectively, which reduced significantly compare with before treatment (88.691 ± 33.775, P< 0.05). The VAS of dysmenorrheal dropped continuously and significantly from the baseline score of (74.968 ± 15.889) to (38.797 ± 16.781), (24.857 ± 16.595), (15.840 ± 14.305), (10.784 ± 13.593) and (8.196 ± 12.919), respectively, after treatment 1, 3, 6, 12, and after 18 months of the LNG-IUS insertion (P < 0.05). The results of SF-36 Health Survey shown the quality of life was significantly improved. Conclusion: These data suggest that LNG-IUS is a safe and effective option for reduces menorrhagia, relieve dysmenorrhea and improve the quality of life in patients with adenomyosis from perimenopausal women.